Will Big Changes At Apricus Biosciences Make It A Winning Stock?
See article on Alpha, Forbes Will Big Changes At Apricus Biosciences Make It A Winning Stock?
The company's products pipeline includes:
Vitaros for the treatment of erectile dysfunction (ED);
Femprox to treat female sexual arousal disorder (FSAD);
MycoVa for the treatment of onychomycosis; and
RayVa to treat Raynaud's Syndrome.
In December 2012, Apricus decided to divest its United States oncology supportive care products in order to focus its resources on Vitaros, Femprox and other drug candidates.